Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (9): 1075-1080.doi: 10.12092/j.issn.1009-2501.2018.09.018

Previous Articles    

Research progress of IL33/ST2 in acute coronary syndrome

ZHANG Qian1, FU Hong2, CHEN Jinjin1, ZHU Yubing1   

  1. 1 Department of Pharmacy, Nanjing First Hospital, Nanjing 210006, Jiangsu, China; 2 College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
  • Received:2018-02-23 Revised:2018-07-13 Online:2018-09-26 Published:2018-09-26

Abstract:

The interleukin-33 (IL-33), which is a new member of the Interleukin-1(IL-1) immunoglobulin family, binds to the target cell membrane growth-stimulating expression gene 2 (ST2) to form a trans membrane complex. The IL-33/ST2 signaling pathway is involved in many inflammatory and immune diseases with the activation of Th2. In recent years, many studies have reported that IL-33/ST2 signaling pathway also plays an important role in cardio- and cerebro-vascular diseases such as coronary heart disease. Acute coronary syndrome (ACS) is a serious type of coronary heart disease based on the process of plaque rupture and erosion following the inflammatory lesions of coronary artery. This article aims to provide a new target and idea for the treatment of acute coronary syndrome by reviewing the progress of the studies of IL-33/ST2 signaling in acute coronary syndrome.

Key words: interleukin-33, growth-stimulating expression gene 2, acute coronary syndrome

CLC Number: